{"id":"js105","safety":{"commonSideEffects":[{"rate":"null","effect":"Increased risk of genital yeast infections"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"By inhibiting SGLT2, JS105 reduces glucose reabsorption in the kidneys, leading to decreased blood glucose levels. This mechanism is particularly useful in the treatment of type 2 diabetes.","oneSentence":"JS105 is a small molecule that targets the SGLT2 receptor.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:49:04.008Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Type 2 diabetes"}]},"trialDetails":[{"nctId":"NCT07207070","phase":"PHASE3","title":"A Randomised, Open-label, Multicentre Phase III Clinical Study to Evaluate the Efficacy and Safety of JS105 Combined With Dalpiciclib and Fulvestrant Compared With Dalpiciclib and Fulvestrant in Patients With PIK3CA-mutated, HR-positive, HER2-negative Recurrent or Metastatic Breast Cancer.","status":"RECRUITING","sponsor":"Risen (Suzhou) Pharma Tech Co., Ltd.","startDate":"2025-11-12","conditions":"Breast Cancer","enrollment":312},{"nctId":"NCT06846099","phase":"PHASE1","title":"A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Efficacy and Indications of RP903","status":"COMPLETED","sponsor":"Risen (Suzhou) Pharma Tech Co., Ltd.","startDate":"2022-12-07","conditions":"Ovarian Cancer, Cervical Cancer, Endometrial Cancer","enrollment":69},{"nctId":"NCT06208410","phase":"PHASE1, PHASE2","title":"A Clinical Study of JS105 in Combination With Other Anti-tumor Therapies in Patients With Solid Tumors","status":"RECRUITING","sponsor":"Risen (Suzhou) Pharma Tech Co., Ltd.","startDate":"2024-01-11","conditions":"Advanced Solid Tumors","enrollment":306}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":1,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"JS105","genericName":"JS105","companyName":"Risen (Suzhou) Pharma Tech Co., Ltd.","companyId":"risen-suzhou-pharma-tech-co-ltd","modality":"Small molecule","firstApprovalDate":"","aiSummary":"JS105 is a small molecule that targets the SGLT2 receptor. Used for Type 2 diabetes.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}